Treatment of Limited Small Cell Lung Cancer with VP-16/ Cis-Platinum, Alternating with Vincristine/Adriamycin/Cyclophosphamide and Radiation Therapy Versus Concurrent VP-16/Vincristine/Adriamycin/Cyclophosphamide and Radiation Therapy

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy. A Southwest Oncology Group study.

GE Goodman;J Crowley;JC Blasko;RB Livingston;TM Beck;MD Demattia;RM Bukowski JCO 8(1):39-47

Determinants of improved outcome in small cell lung cancer: An analysis of 2,580-patient Southwest Oncology Group data base.

KS Albain;JJ Crowley;M LeBlanc;RB Livingston JCO 8(9):1563-1574

Concurrent chemotherapy with VP-16/vincristine/adriamycin/cyclophosphamide (EVAC) versus alternating chemotherapy withVP-16/cis-platinum and vincristine/adriamycin/cyclophosphamide(VPP/VAC) in limited small cell lung cancer (SCLC): A Southwest Oncology Group study (SWOG).

GE Goodman;J Basko ASCO 5:169(#663)

Concurrent chemotherapy with VP-16/vincristine/adriamycin/cyclophosphamide (EVAC) versus alternating chemotherapy with VP-16/cis-platinum and vincristine/adriamycin/cyclophosphamide(VPP/VAC) in limited small cell lung cancer (SCLC): A Southwest Oncology Group (SWOG) study.

GE Goodman;J Basko Proc ASCO 5:169 (#663)